SODIUM ROSE BENGAL I 131
Pre-Launchrose bengal sodium i-131
NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 20h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sodium Rose Bengal I-131 is a radioiodinated diagnostic agent administered by injection, primarily used for hepatic imaging and assessment of liver function. This is a radiopharmaceutical that localizes in the liver to enable visualization and evaluation of hepatic disorders. The product is in pre-launch stage, indicating it has not yet reached commercial availability.
Pre-Launch
Pre-launch diagnostic radiopharmaceutical with limited immediate market visibility; team size and investment depend on regulatory approval timeline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Sodium Rose Bengal I-131 offers entry into the specialized radiopharmaceutical sector, with career growth tied to regulatory approval and market launch success. This pre-launch role is best suited for professionals seeking foundational experience in drug development, regulatory strategy, or diagnostic imaging commercialization.
Regulatory Affairs SpecialistMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.